Coronavirus vaccine: Novavax begins human trials in Australia

&Tab;&Tab;<div class&equals;"wpcnt">&NewLine;&Tab;&Tab;&Tab;<div class&equals;"wpa">&NewLine;&Tab;&Tab;&Tab;&Tab;<span class&equals;"wpa-about">Advertisements<&sol;span>&NewLine;&Tab;&Tab;&Tab;&Tab;<div class&equals;"u top&lowbar;amp">&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;<amp-ad width&equals;"300" height&equals;"265"&NewLine;&Tab;&Tab; type&equals;"pubmine"&NewLine;&Tab;&Tab; data-siteid&equals;"111265417"&NewLine;&Tab;&Tab; data-section&equals;"1">&NewLine;&Tab;&Tab;<&sol;amp-ad>&NewLine;&Tab;&Tab;&Tab;&Tab;<&sol;div>&NewLine;&Tab;&Tab;&Tab;<&sol;div>&NewLine;&Tab;&Tab;<&sol;div><p>Human trials for a coronavirus vaccine have begun in Australia as US biotechnology company Novavax hopes to release a proven jab this year&period;<&sol;p>&NewLine;<p>The company said 131 volunteers in Melbourne and Brisbane are being used to test the safety and effectiveness of the vaccine&period;<&sol;p>&NewLine;<p>Animal testing suggested it is effective in low doses&comma; and Novavax could manufacture at least 100 million doses this year and 1&period;5 billion in 2021&comma; the company’s research chief Dr Gregory Glenn said&period;<&sol;p>&NewLine;<p>He added&colon; <i>&OpenCurlyDoubleQuote;We are in parallel making doses&comma; making vaccine in anticipation that we’ll be able to show it’s working and be able to start deploying it by the end of this year&period;”<&sol;i><&sol;p>&NewLine;<p>Manufacture of the vaccine&comma; named NVX-CoV2373&comma; was being scaled up with 388 million dollars &lpar;£318 million&rpar; invested by Norway-based Coalition for Epidemic Preparedness Innovations since March&comma; Dr Glenn said&period;<&sol;p>&NewLine;<blockquote class&equals;"twitter-tweet" data-width&equals;"550" data-dnt&equals;"true">&NewLine;<p lang&equals;"en" dir&equals;"ltr"><a href&equals;"https&colon;&sol;&sol;twitter&period;com&sol;search&quest;q&equals;&percnt;24NVAX&amp&semi;src&equals;ctag&amp&semi;ref&lowbar;src&equals;twsrc&percnt;5Etfw">&dollar;NVAX<&sol;a> is very excited to have just announced initiation of the <a href&equals;"https&colon;&sol;&sol;twitter&period;com&sol;hashtag&sol;phase1&quest;src&equals;hash&amp&semi;ref&lowbar;src&equals;twsrc&percnt;5Etfw">&num;phase1<&sol;a> portion of the Phase 1&sol;2 clinical trial for <a href&equals;"https&colon;&sol;&sol;twitter&period;com&sol;hashtag&sol;NVXCoV2373&quest;src&equals;hash&amp&semi;ref&lowbar;src&equals;twsrc&percnt;5Etfw">&num;NVXCoV2373<&sol;a>&comma; our <a href&equals;"https&colon;&sol;&sol;twitter&period;com&sol;hashtag&sol;COVID19&quest;src&equals;hash&amp&semi;ref&lowbar;src&equals;twsrc&percnt;5Etfw">&num;COVID19<&sol;a> <a href&equals;"https&colon;&sol;&sol;twitter&period;com&sol;hashtag&sol;vaccine&quest;src&equals;hash&amp&semi;ref&lowbar;src&equals;twsrc&percnt;5Etfw">&num;vaccine<&sol;a> &period; Read our news release to learn more to learn more at <a href&equals;"https&colon;&sol;&sol;t&period;co&sol;bDOaGeRtzt">https&colon;&sol;&sol;t&period;co&sol;bDOaGeRtzt<&sol;a>&period; <a href&equals;"https&colon;&sol;&sol;twitter&period;com&sol;hashtag&sol;novavax2020&quest;src&equals;hash&amp&semi;ref&lowbar;src&equals;twsrc&percnt;5Etfw">&num;novavax2020<&sol;a> <a href&equals;"https&colon;&sol;&sol;t&period;co&sol;5vdmjA0THI">pic&period;twitter&period;com&sol;5vdmjA0THI<&sol;a><&sol;p>&NewLine;<p>&mdash&semi; Novavax &lpar;&commat;Novavax&rpar; <a href&equals;"https&colon;&sol;&sol;twitter&period;com&sol;Novavax&sol;status&sol;1265028606264324096&quest;ref&lowbar;src&equals;twsrc&percnt;5Etfw">May 25&comma; 2020<&sol;a><&sol;p><&sol;blockquote>&NewLine;<p><script async src&equals;"https&colon;&sol;&sol;platform&period;twitter&period;com&sol;widgets&period;js" charset&equals;"utf-8"><&sol;script><&sol;p>&NewLine;<p>The trial began with six volunteers being injected with the potential vaccine in Melbourne on Tuesday&comma; said Paul Griffin&comma; infectious disease expert with Australian collaborator Nucleus Network&period;<&sol;p>&NewLine;<p>About a dozen experimental vaccines are in early stages of testing or poised to start&comma; mostly in China&comma; the US and Europe&period;<&sol;p>&NewLine;<p>It is not clear that any of the candidates ultimately will prove safe and effective&comma; but many work in different ways and are made with different technologies&comma; increasing the odds that at least one approach might succeed&period;<&sol;p>&NewLine;<p>The results of the first phase of clinical trials in Australia are expected to be known in July&comma; Novavax said&comma; and thousands of candidates in several countries would then become involved in a second phase&period;<&sol;p>&NewLine;<p>Most of the vaccines in the pipeline aim to train the immune system to recognise the &OpenCurlyDoubleQuote;<i>spike<&sol;i>” protein that studs the coronavirus’ outer surface&comma; priming the body to react if it ever encountered the real infection&period;<&sol;p>&NewLine;<p>Some candidates are made using just the genetic code for that protein&comma; and others use a harmless virus to deliver the protein-producing information&period;<&sol;p>&NewLine;<p>The Novavax jab is a recombinant vaccine – where genetic engineering is used to grow harmless copies of the coronavirus spike protein which is treated like the virus by the immune system&period;<&sol;p>&NewLine;&Tab;&Tab;&Tab;<div style&equals;"padding-bottom&colon;15px&semi;" class&equals;"wordads-tag" data-slot-type&equals;"belowpost">&NewLine;&Tab;&Tab;&Tab;&Tab;<div id&equals;"atatags-dynamic-belowpost-68ed19559c3b4">&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;<script type&equals;"text&sol;javascript">&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;getAdSnippetCallback &equals; function &lpar;&rpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;if &lpar; false &equals;&equals;&equals; &lpar; window&period;isWatlV1 &quest;&quest; false &rpar; &rpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&sol;&sol; Use Aditude scripts&period;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;tudeMappings &equals; window&period;tudeMappings &vert;&vert; &lbrack;&rsqb;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;tudeMappings&period;push&lpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;divId&colon; 'atatags-dynamic-belowpost-68ed19559c3b4'&comma;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;format&colon; 'belowpost'&comma;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub; &rpar;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub;&NewLine;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;if &lpar; document&period;readyState &equals;&equals;&equals; 'loading' &rpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;document&period;addEventListener&lpar; 'DOMContentLoaded'&comma; window&period;getAdSnippetCallback &rpar;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub; else &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;getAdSnippetCallback&lpar;&rpar;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;<&sol;script>&NewLine;&Tab;&Tab;&Tab;&Tab;<&sol;div>&NewLine;&Tab;&Tab;&Tab;<&sol;div>


Discover more from London Glossy Post

Subscribe to get the latest posts sent to your email.

- Advertisement -
Exit mobile version